Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577801 | 0.98 | ESR1 (0.40) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577833 | 0.96 | PARP1 (0.40) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577865 | 0.96 | ESR1 (0.41) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577847 | 0.94 | MEN1 (0.40) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577825 | 0.94 | PARP1 (0.40) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577813 | 0.93 | PARP1 (0.37) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577820 | 0.92 | PARP1 (0.39) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577881 | 0.90 | CYP1A1 (0.41) | ESR1ESR2PARP1CYP1A1CYP1B1 | |
| SCHEMBL12577807 | 0.90 | ALDH1A1 (0.40) | ESR1ESR2CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL12577857 | 0.90 | CYP1A2 (0.40) | CYP1A1CYP1B1CYP1A2MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318325-B2 | Anthracene derivatives and organic electronic device using same | LG CHEM, LTD. (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8318325-B2 | Anthracene derivatives and organic electronic device using same | LG CHEM, LTD. (KR) | 2012-11-27 | — | — | US | disclosed |
| US-20110156017-A1 | NOVEL ANTHRACENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2011-06-30 | — | — | US | disclosed |
| US-20110156017-A1 | NOVEL ANTHRACENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110156017-A1 | NOVEL ANTHRACENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING SAME | VDAC2, VDAC3, ANXA1 | ESR1 57/4885ESR2 538/4885PARP1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.